Carl Hull

Carl Hull brings to Maravai LifeSciences over 35 years of sales, marketing and general management leadership in the diagnostics and life sciences industries. Prior to founding Maravai LifeSciences, Mr. Hull was CEO of Gen-Probe, where he had been recruited in 2007 as part of a board-directed succession plan for the CEO. He focused the company strategy to take full advantage of its core molecular diagnostics and automation strengths. During this time, Gen-Probe launched several highly innovative products including the PANTHER® molecular diagnostic system and APTIMA® HPV screening assay. As a result, the company extended its recognized leadership position in the most rapidly growing diagnostics market segment. During his tenure, the value of Gen-Probe doubled, creating nearly $2 billion in value for shareholders and culminating in a successful sale of the business in 2012 to Hologic. Earlier in his career, Mr. Hull had been in sales, marketing and management positions for Abbott Laboratories, Ventana Medical Systems (acquired by Roche), Applied Imaging (now part of Danaher) and Applied Biosystems (now part of Thermo Fisher Scientific). Mr. Hull serves as Chairman of the Board for The Binding Site and is a member of the Board of Ortho Clinical Diagnostics, both leading human diagnostics companies. Mr. Hull holds an MBA from the University of Chicago and a B.A. in Political Science and International Relations from the Johns Hopkins University.